{"https://www.hss.edu/conditions_patient-guide-opioid-tapering.asp": {"url": "https://www.hss.edu/conditions_patient-guide-opioid-tapering.asp", "description": "Opioid therapy helps manage short-term pain caused by surgery. Learn about tapering or gradual reduction, which is a vital part of the healing process.", "snippets": ["Do not substitute alcohol or other substances to help with tapering down. It is vital for patients, caregivers, and physicians to be vigilant about opioid use and the process of tapering off of these medications. This article should not be viewed as medical advice.", "Physicians and patients should work together to develop a treatment plan to manage withdrawal symptoms. Fast tapering is the process of stopping all opioids or reducing opioids quickly over a few days to a week, decreasing the total daily dose by 20% to 25% every few days to minimize withdrawal symptoms.", "Patients who may benefit from tapering off their opioid regimens should do so under the management of a physician. Prescription opioids include but are not limited to the following: ... While opioids remain a significant and essential part of some patients\u2019 healing requirements, opioid use needs to be tailored to each individual and their postsurgical pain levels. There are many effects linked to long-term opioid use which patients should consider:", "Patients who are already using opioids to treat their pain before coming into surgery tend to require much higher doses of opioids after surgery. This puts them at a higher risk of developing opioid-related side effects and may lead to longer hospital stays or even negatively influence their surgical outcomes. Some patients may feel withdrawal symptoms if they taper off of opioids too quickly, depending on their history of opioid use and their pain.", "This puts them at a higher risk of developing opioid-related side effects and may lead to longer hospital stays or even negatively influence their surgical outcomes. Some patients may feel withdrawal symptoms if they taper off of opioids too quickly, depending on their history of opioid use and their pain.", "Shorter intervals of time or higher percentage decreases of opiod doses will usually cause severe withdrawal symptoms. Most physicians typically recommend close monitoring and/or supervised centers for patients considering a fast tapering program.", "For patients who may require more extensive or high-dose opioid use, or who have a history of opioid use, tapering (gradual reduction) is a vital part of the healing process. Patients who may benefit from tapering off their opioid regimens should do so under the management of a physician.", "It is vital for patients, caregivers, and physicians to be vigilant about opioid use and the process of tapering off of these medications. This article should not be viewed as medical advice.", "Some patients that have been on high-dose opioids may experience generalized tiredness or feel unwell for a few weeks. Patients who have been taking opioids long-term (more than six months) should discuss with their physician their desire to decrease their opioid use. Physicians and patients should work together to develop a treatment plan to manage withdrawal symptoms. Fast tapering is the process of stopping all opioids or reducing opioids quickly over a few days to a week, decreasing the total daily dose by 20% to 25% every few days to minimize withdrawal symptoms.", "Fast tapering is the process of stopping all opioids or reducing opioids quickly over a few days to a week, decreasing the total daily dose by 20% to 25% every few days to minimize withdrawal symptoms. Shorter intervals of time or higher percentage decreases of opiod doses will usually cause severe withdrawal symptoms.", "Patients who have been taking opioids long-term (more than six months) should discuss with their physician their desire to decrease their opioid use. Physicians and patients should work together to develop a treatment plan to manage withdrawal symptoms. Fast tapering is the process of stopping all opioids or reducing opioids quickly over a few days to a week, decreasing the total daily dose by 20% to 25% every few days to minimize withdrawal symptoms.", "While this is unique to every patient, in most instances, the body has not developed tolerance during that time frame. For patients who have been taking more than six tablets per day, tapering use down by one tablet every 2 to 3 days is recommended (see a detailed tapering plan for these instances below).", "Patients who may benefit from tapering off their opioid regimens should do so under the management of a physician. Prescription opioids include but are not limited to the following: ... While opioids remain a significant and essential part of some patients\u2019 healing requirements, opioid use needs to be tailored to each individual and their postsurgical pain levels.", "Patients may be prescribed a short dose of opioid therapy to help manage short-term pain caused by surgery. For patients who may require more extensive or high-dose opioid use, or who have a history of opioid use, tapering (gradual reduction) is a vital part of the healing process.", "Use relaxation techniques, which can include breathing exercises, music therapy, guided imagery, meditation and reading. Keep a positive outlook and surround yourself with people to keep your moo.d positive. Do not substitute alcohol or other substances to help with tapering down.", "Some patients may feel withdrawal symptoms if they taper off of opioids too quickly, depending on their history of opioid use and their pain.", "Slow tapering is the process of decreasing total daily opioid doses by 10% to 25% every 1 to 3 weeks with close follow-up with a physician. Depending on the patient\u2019s use prior to starting the slow taper, dose of an opioid may be decreased first before increasing the time interval between doses."], "title": "A Patient\u2019s Guide to Opioid Tapering | HSS"}, "https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf": {"url": "https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf", "description": "Preventing drug overdose and reducing substance use-related harms is a CDC priority.", "snippets": [], "title": "Pocket Guide: Tapering Opioids for Chronic Pain"}, "https://www.aafp.org/pubs/afp/issues/2020/0101/p49.html": {"url": "https://www.aafp.org/pubs/afp/issues/2020/0101/p49.html", "description": "The standard recommendation to decrease opioid doses by 5% to 10% of the starting dose every one to two weeks8 is intolerable for many patients using long-term opioid therapy for chronic pain. Many patients need to decrease by less than 5% every month, with even smaller decrements toward the ...", "snippets": ["The standard recommendation to decrease opioid doses by 5% to 10% of the starting dose every one to two weeks8 is intolerable for many patients using long-term opioid therapy for chronic pain. Many patients need to decrease by less than 5% every month, with even smaller decrements toward the end of the taper.9 Some patients require many months to wean off chronic opioid therapy, especially those who have taken opioids daily for decades.", "During the past year, he has admitted that he feels \u201cstuck on these drugs.\u201d His pain is not well controlled, and his wife has complained that he seems \u201cout of it.\u201d We have talked about reducing his prescription or stopping opioids, but he is reluctant and worried. How can I help my patient taper his regimen to minimize withdrawal and maximize his chances for success?", "My patient is a 54-year-old construction worker who has been taking prescribed opioids for more than a decade for chronic knee and back pain.", "Begin by telling the patient, \u201cI\u2019ve been thinking a lot about your chronic pain.\u201d This communicates that the benefit of an opioid taper has been carefully considered and that the plan for a taper is not impulsive or retaliatory. It is rather the result of careful deliberation, including medical assessment of risk vs. benefit. Arrange extra time to discuss this delicate topic. Anticipate the patient\u2019s strong emotional reaction. Pledge your support through this difficult process."], "title": "Tapering Long-Term Opioid Therapy | AAFP"}, "https://www.samhsa.gov/find-help/national-helpline": {"url": "https://www.samhsa.gov/find-help/national-helpline", "description": "SAMHSA\u2019s National Helpline is a free, confidential, 24/7, 365-day-a-year treatment referral and information service (in English and Spanish) for individuals and families facing mental and/or substance use disorders.", "snippets": ["Family Therapy Can Help: For People in Recovery From Mental Illness or Addiction Explores the role of family therapy in recovery from mental illness or substance abuse."], "title": "SAMHSA\u2019s National Helpline | SAMHSA"}, "https://www.addictioncenter.com/opiates/oxycodone/": {"url": "https://www.addictioncenter.com/opiates/oxycodone/", "description": "Not only is it an expensive and debilitating addiction, overdose from oxycodone is a very real \u2014 and potentially deadly \u2014 possibility. People who are suffering from an oxycodone use disorder usually require a medically managed detox and a good treatment program to prevent relapse.", "snippets": ["Roxicodone is a rapid-release formula of oxycodone that is used to treat moderate to severe pain. It is often given to a patient before surgery to sedate or calm them and for around-the-clock pain management. When abused, the drug causes a very quick high in the user.", "Addiction Center Your guide for addiction and recovery \u00b7 Treatment providers are waiting for your call: Calls are forwarded to these paid advertisers ... Oxycodone, a potent painkiller, comes in many forms and is among the most addictive drugs available by prescription.", "Oxycodone is used in many painkillers. Oxycodone addiction comes with many dangers and side effects, some of which are detailed here.", "Many people who abuse oxycodone start out by taking a prescribed amount \u2014 but as their body develops a tolerance to the drug, they need a higher dose to maintain the same relief or high. The transition from use to abuse to addiction can be quick and dangerous."], "title": "Oxycodone Addiction And Abuse - A Potent Painkiller"}, "https://nida.nih.gov/research-topics/opioids": {"url": "https://nida.nih.gov/research-topics/opioids", "description": "Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription.", "snippets": ["Opioids are a class of drugs that include synthetic opioids such as fentanyl; pain relievers available legally by prescription, such as oxycodone (OxyContin\u00ae), hydrocodone (Vicodin\u00ae), codeine, morphine; the illegal drug heroin; and many others.", "NIDA plays a leading role in the National Institutes of Health HEAL (Helping to End Addiction Long-term\u00ae) Initiative, an effort to develop new scientific solutions to the national opioid addiction and overdose public health crisis and to improve pain management."], "title": "Opioids | National Institute on Drug Abuse (NIDA)"}, "https://www.mayoclinic.org/diseases-conditions/prescription-drug-abuse/in-depth/tapering-off-opioids-when-and-how/art-20386036": {"url": "https://www.mayoclinic.org/diseases-conditions/prescription-drug-abuse/in-depth/tapering-off-opioids-when-and-how/art-20386036", "description": "Most people using opioid medicines need to stop as soon as possible to prevent serious health risks. Learn how to slowly lower and safely stop opioid use.", "snippets": [], "title": "Tapering off opioids: When and how - Mayo Clinic"}, "https://mn.gov/dhs/opip/opioid-guidelines/tapering-opioids/": {"url": "https://mn.gov/dhs/opip/opioid-guidelines/tapering-opioids/", "description": "The taper may reveal underlying ... by opioid therapy, or the taper itself may illicit depression and anxiety which needs to be addressed. Research examining the use of behavioral health care during a taper suggest that integrating therapies before and during a taper can help manage pain and improve the likelihood of tapering success. (Frank, 2017) Access to behavioral health therapy is a challenge, especially ...", "snippets": ["Tapering opioids well requires time, compassion, empathy, education and support for patients. This guidance, as well as the US Health and Human Services\u2019 guidance, the Veterans Affairs Taper Decision tool and various state-level recommendations on tapering recommend including behavioral health providers on the treatment team (HHS, 2019; VA Taper Decision Tool, BRAVO guidance).", "A detailed process for tapering and discontinuing opioid use in situations with chronic opioid analgesic treatment (COAT)", "Clinicians should be aware that not every risk benefit analysis will indicate a taper is needed to improve the patient\u2019s risk profile. In addition, for some patients long-term opioid therapy may be a useful component of multidisciplinary care, e.g., some cases of sickle cell disease, hospice, palliative care, and pain management for certain cancers.", "Effort must be made to ensure the patient can self-report problems with the taper and other issues without fear of judgment, and providers must be willing to halt or discontinue the taper depending on the patient\u2019s circumstances. Continually provide patients reassurance and convey your confidence in their ability to achieve their goals. Make yourself or a team member available to the patient to provide support, if needed (VA Opioid Decision Taper Tool, 2019).", "The taper may reveal underlying mental health conditions that were previously masked by opioid therapy, or the taper itself may illicit depression and anxiety which needs to be addressed. Research examining the use of behavioral health care during a taper suggest that integrating therapies before and during a taper can help manage pain and improve the likelihood of tapering success. (Frank, 2017) Access to behavioral health therapy is a challenge, especially in rural areas.", "In order to determine whether a taper is indicated, providers must complete and document a thorough, thoughtful risk benefit analysis (RBA) of continuing opioid therapy at the current dose. A thorough RBA requires a depth of knowledge about the patient\u2019s circumstances, which is why tapers should occur within a strong, therapeutic alliance.", "A taper is a reduction in daily opioid dosage done to improve a patient\u2019s safety profile or quality of life. A successful taper reflects shared decision making and can result in either a lower daily dose, or discontinuation of opioid therapy, dependent on the patient\u2019s goals and risk profile."], "title": "Tapering and discontinuing opioid use / Minnesota Opioid Guidelines"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349552/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349552/", "description": "This study used interview and focus ... productive, patient-centered discussions of opioid tapering. Findings will inform further research on tapering and help primary care clinicians to address this important, often challenging topic....", "snippets": ["This study used interview and focus group data to characterize patients\u2019 experiences with opioid tapering and identify communication strategies that are likely to foster productive, patient-centered discussions of opioid tapering. Findings will inform further research on tapering and help primary care clinicians to address this important, often challenging topic.", "Patients were often reluctant to challenge clinicians for fear of losing access to other medical services or of being labeled a \u201cdrug seeker.\u201d \u00b7 For several patients, tapering discussions were precipitated by clinician retirement. Other patients noted they had trouble finding primary care clinicians willing to prescribe opioids when they needed to change clinicians. As shown in the excerpts below, changing clinicians is one of the few options patients have for resolving persistent disagreements about tapering and opioids.", "Transcripts were qualitatively analyzed to characterize patients\u2019 tapering experiences, build a conceptual model of these experiences, and identify strategies for promoting productive discussions of opioid tapering. Analyses revealed 3 major themes. First, due to dynamic changes in patients\u2019 social relationships, emotional state, and health status, patients\u2019 pain and perceived need for opioids fluctuate daily; this may conflict with recommendations to taper by a certain amount each month.", "Clinical guidelines discourage prescribing opioids for chronic pain but give minimal advice about how to discuss opioid tapering with patients. We conducted focus groups and interviews involving 21 adults with chronic back or neck pain in different stages of opioid tapering."], "title": "Patients\u2019 experience with opioid tapering: A conceptual model with recommendations for clinicians - PMC"}, "https://www.health.harvard.edu/blog/undoing-the-harm-tapering-down-from-high-dose-opioids-2019051016622": {"url": "https://www.health.harvard.edu/blog/undoing-the-harm-tapering-down-from-high-dose-opioids-2019051016622", "description": "The CDC\u2019s Guideline on Prescribing Opioids for Chronic Pain helps doctors and patients manage treatment at safe levels and avoid dependence. Any plan to taper medication dosage should ...", "snippets": ["Although some of these steps may feel punitive, they are designed to keep you safe and prevent you from developing an addiction. Additionally, in light of recent evidence demonstrating that opioids provide only limited benefit for chronic non-cancer pain, and given their known dangers, this may be the time to discuss a gradual tapering of opioids on a schedule that both you and your provider are comfortable with.", "A 5-mg dose of oxycodone equals 7.5 MMEs, so you would reach the 90 MME threshold by taking 12 or more of these pills per day. The guidelines raised several concerns among patients with chronic pain on high-dose opioids, as well as the providers who cared for them. Should patients on more than 90 MME be abruptly cut off? Should a rapid taper occur to get to the safe upper limit?", "The guideline recommends creating personalized plans for tapering, ensuring that it be slow enough to minimize opioid withdrawal, for example a 10% a week or even 10% a month decrease for those who have been on high-dose opioids for years.", "The CDC\u2019s Guideline on Prescribing Opioids for Chronic Pain helps doctors and patients manage treatment at safe levels and avoid dependence. Any plan to taper medication dosage should be personalized to the patient\u2019s needs.", "The guideline does not endorse mandated or abrupt dose reduction or discontinuation. The guideline recommends tapering only when patient harm outweighs the benefit of opioid therapy.", "Since 1999, sales of prescription opioids in the U.S. have nearly quadrupled. The good news is that there are a number of effective interventions for opioid addiction. These include self-help strategies, psychotherapy, medications, and rehabilitation programs.", "They continue: \"When you and your patient have agreed to taper the dose of opioid analgesic, consider a variety of factors, including the dose of the drug, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.", "The guideline recommends creating personalized plans for tapering, ensuring that it be slow enough to minimize opioid withdrawal, for example a 10% a week or even 10% a month decrease for those who have been on high-dose opioids for years. The authors of the CDC guideline also responded with their own similar article in the New England Journal of Medicine. The FDA also weighed in, stating that opioids should not be abruptly discontinued in patients who have physical dependence. They continue: \"When you and your patient have agreed to taper the dose of opioid analgesic, consider a variety of factors, including the dose of the drug, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient."], "title": "Undoing the harm: Tapering down from high-dose opioids - Harvard Health"}, "https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes": {"url": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes", "description": "FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering", "snippets": ["If the patient is experiencing increased pain or serious withdrawal symptoms, it may be necessary to pause the taper for a period of time, raise the opioid analgesic to the previous dose, and then once stable, proceed with a more gradual taper. When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.", "Create a patient-specific plan to gradually taper the dose of the opioid and ensure ongoing monitoring and support, as needed, to avoid serious withdrawal symptoms, worsening of the patient\u2019s pain, or psychological distress (For tapering and additional recommendations, see Additional Information for Health Care Professionals).", "Opioids are a class of powerful prescription medicines that are used to manage pain when other treatments and medicines cannot be taken or are not able to provide enough pain relief. They have serious risks, including abuse, addiction, overdose, and death. Examples of common opioids include codeine, fentanyl, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone. Health care professionals should not abruptly discontinue opioids in a patient who is physically dependent. When you and your patient have agreed to taper the dose of opioid analgesic, consider a variety of factors, including the dose of the drug, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.", "Patients who have been taking opioids for shorter time periods may tolerate a more rapid taper. Frequent follow-up with patients is important. Reassess the patient regularly to manage pain and withdrawal symptoms that emerge. Common withdrawal symptoms include:", "Examples of common opioids include codeine, fentanyl, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone. Health care professionals should not abruptly discontinue opioids in a patient who is physically dependent. When you and your patient have agreed to taper the dose of opioid analgesic, consider a variety of factors, including the dose of the drug, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.", "The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. ... FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering ... [4-9-2019] The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased.", "The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. ... FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering", "Create a patient-specific plan to gradually taper the dose of the opioid and ensure ongoing monitoring and support, as needed, to avoid serious withdrawal symptoms, worsening of the patient\u2019s pain, or psychological distress (For tapering and additional recommendations, see Additional Information for Health Care Professionals). Patients taking opioid pain medicines long-term should not suddenly stop taking your medicine without first discussing with your health care professional a plan for how to slowly decrease the dose of the opioid and continue to manage your pain.", "FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering ... [4-9-2019] The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide.", "It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When deciding how to discontinue or decrease therapy in an opioid-dependent patient, consider a variety of factors, including the dose of the opioid analgesic the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.", "Counsel patients not to discontinue their opioids without first discussing the need for a gradual tapering regimen. Abrupt or inappropriately rapid discontinuation of opioids in patients who are physically dependent has been associated with serious withdrawal symptoms, uncontrolled pain, and suicide.", "A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic.", "Patients who have been taking opioids for shorter time periods may tolerate a more rapid taper. Frequent follow-up with patients is important. Reassess the patient regularly to manage pain and withdrawal symptoms that emerge.", "Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic."], "title": "FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering | FDA"}, "https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf": {"url": "https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Pain_Opioid_Taper_Tool_IB_10_939_P96820.pdf", "description": "Apply for and manage the VA benefits and services you\u2019ve earned as a Veteran, Servicemember, or family member\u2014like health care, disability, education, and more.", "snippets": [], "title": "Pain Management Opioid Taper Decision Tool"}, "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm": {"url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm", "description": "This report describes CDC\u2019s updated clinical practice guideline for prescribing opioids for pain.", "snippets": ["Such misapplication includes extension to patient populations not covered in the 2016 CDC Opioid Prescribing Guideline (e.g., cancer and palliative care patients), rapid opioid tapers and abrupt discontinuation without collaboration with patients, rigid application of opioid dosage thresholds, application of the guideline\u2019s recommendations for opioid use for pain to medications for opioid use disorder treatment (previously referred to as medication assisted treatment), duration limits by insurers and pharmacies, and patient dismissal and abandonment (66\u201368).", "This evidence includes studies on misapplication of the 2016 CDC Opioid Prescribing Guideline (66), benefits and risks of different tapering strategies and rapid tapering associated with patient harm (68,71\u201373), challenges in patient access to opioids (6), patient abandonment and abrupt discontinuation of opioids (71), a seminal randomized clinical trial comparing prescription opioids to nonopioid medications on long-term pain outcomes (74), the association of characteristics of initial opioid prescriptions with subsequent likelihood for long-term opioid use (75,76), and the small proportion of opioids used by patients compared with the amount prescribed to them for postoperative pain (77\u201379).", "Discontinuing opioids after extended periods of continuous opioid use can be challenging for clinicians and patients. Tapering or discontinuing opioids in patients who have taken them long term can be associated with clinically significant risks (68), particularly if opioids are tapered rapidly or patients do not receive effective support.", "To minimize withdrawal symptoms, clinicians should provide and discuss an opioid tapering plan when opioids will be used around the clock for more than a few days (see Recommendation 6). Limiting opioid use to the minimum needed to manage pain (e.g., taking the opioid only when needed if needed less frequently than every 4 hours and the prescription is written for every 4 hours as needed for pain) can help limit development of tolerance and therefore withdrawal after opioids are discontinued.", "A multimodal and multidisciplinary approach to pain management attending to the physical health, behavioral health, long-term services and supports, and expected health outcomes and well-being of each person is critical.", "If patients receiving long-term opioid therapy require additional medication for acute pain, nonopioid medications should be used when possible. If additional opioids are required (e.g., for superimposed severe acute pain), they should be continued only for the duration of pain severe enough to require additional opioids, returning to the patient\u2019s baseline opioid dosage as soon as possible, including an appropriate taper to baseline dosage if additional opioids were used around the clock for more than a few days (see Recommendation 6).", "Advise patients that short-term opioid use can lead to unintended long-term opioid use and of the importance of working toward planned discontinuation of opioid use as soon as feasible, including a plan to appropriately taper opioids as pain resolves if opioids have been used around the clock for more than a few days (see Recommendation 6). Review communication mechanisms and protocols patients can use to tell clinicians of severe or uncontrolled pain and to arrange for timely reassessment and management.", "Continuation of opioid therapy at this point might represent initiation of long-term opioid therapy, which should occur only as an intentional decision that benefits are likely to outweigh risks after informed discussion between the clinician and patient and as part of a comprehensive pain management approach. Clinicians seeing new patients already receiving opioids should establish treatment goals, including functional goals, for continued opioid therapy. Clinicians should avoid rapid tapering or abrupt discontinuation of opioids (see Recommendation 5).", "Tapering or discontinuing opioids in patients who have taken them long term can be associated with clinically significant risks (68), particularly if opioids are tapered rapidly or patients do not receive effective support. Patients, caregivers, and clinicians responded to CDC with invited input about their experiences and perspectives related to pain and pain management options.", "No validated, reliable way exists to predict which patients will experience serious harm from opioid therapy and which patients will benefit from opioid therapy (7). Discontinuing opioids after extended periods of continuous opioid use can be challenging for clinicians and patients. Tapering or discontinuing opioids in patients who have taken them long term can be associated with clinically significant risks (68), particularly if opioids are tapered rapidly or patients do not receive effective support.", "Specific effort was made to identify subject matter experts with knowledge and experience in topics such as chronic and acute pain management, clinical practice, health equity, mental health and well-being, opioids and opioid therapies, opioid tapering, opioid use disorder treatment, pharmacologic and nonpharmacologic pain management, and surgical pain management.", "When diagnosis and severity of acute pain warrant the use of opioids, clinicians should prescribe immediate-release opioids (see Recommendation 3) at the lowest effective dose (see Recommendation 4) and for no longer than the expected duration of pain severe enough to require opioids (see Recommendation 6) to minimize unintentional initiation of long-term opioid use. Clinicians should maximize use of nonopioid pharmacologic (e.g., NSAIDs, acetaminophen, or both) and nonpharmacologic (e.g., ice, heat, elevation, rest, immobilization, or exercise) therapies as appropriate for the specific condition and continue these therapies as needed after opioids are discontinued.", "This report describes CDC\u2019s updated clinical practice guideline for prescribing opioids for pain.", "Changes included a boxed warning on the \u201crisks of addiction, abuse, and misuse, which can lead to overdose and death\u201d and, for patients receiving opioids during pregnancy, the risk for neonatal abstinence syndrome (a group of conditions that can occur when newborns withdraw from certain substances including opioids; withdrawal caused by in utero exposure to opioids also is called neonatal opioid withdrawal syndrome) (49).", "Clinicians should recommend appropriate noninvasive nonpharmacologic approaches to help manage chronic pain, such as exercise (e.g., aerobic, aquatic, or resistance exercises) or exercise therapy (a prominent modality in physical therapy) for back pain, fibromyalgia, and hip or knee osteoarthritis; weight loss for knee osteoarthritis; manual therapies for hip osteoarthritis; psychological therapy, spinal manipulation, low-level laser therapy, massage, mindfulness-based stress reduction, yoga, acupuncture, and multidisciplinary rehabilitation for low back pain; mind-body practices (e.g., yoga, tai chi, or qigong), massage, and acupuncture for neck pain; cognitive behavioral therapy, myofascial release massage, mindfulness practices, tai chi, qigong, acupuncture, and multidisciplinary rehabilitation for fibromyalgia; and spinal manipulation for tension headache.", "Clinicians should prescribe and advise opioid use only as needed (e.g., hydrocodone 5 mg/acetaminophen 325 mg, one tablet not more frequently than every 4 hours as needed for moderate to severe pain) rather than on a scheduled basis (e.g., one tablet every 4 hours) and encourage and recommend an opioid taper if opioids are taken around the clock for more than a few days (see Recommendation 6). If patients already receiving opioids long term require additional medication for acute pain, nonopioid medications should be used when possible and, if additional opioids are required (e.g., for superim", "Importantly, the update also aims to clearly delineate recommendations that apply to patients who are being considered for initial treatment with prescription opioids and patients who have been receiving opioids as part of their ongoing pain management. CDC developed a draft clinical practice guideline on the basis of five systematic reviews of the best-available evidence on the benefits and risks of prescription opioids, nonopioid pharmacologic treatments, and nonpharmacologic treatments.", "The AHRQ review of opioids for chronic pain updated and expanded the evidence for the 2016 CDC review; studies were included on short-term (1 to <6 months), intermediate-term (6 to <12 months) and long-term (\u226512 months) outcomes of therapy involving opioids, effects of opioid plus nonopioid combination therapy, effects of tramadol, effects of naloxone coprescription, risks of coprescribed benzodiazepines, risks of coprescribed gabapentinoids, and effects of concurrent use of cannabis (7). The systematic clinical evidence review on opioids for chronic pain (7) also included contextual questio", "If patients already receiving opioids long term require additional medication for acute pain, nonopioid medications should be used when possible and, if additional opioids are required (e.g., for superimposed severe acute pain), they should be continued only for the duration of pain severe enough to require additional opioids, returning to the patient\u2019s baseline opioid dosage as soon as possible, including a taper to baseline dosage if additional opioids were used around the clock for more than a few days (see Recommendation 6). Clinicians should ensure that patients are aware of expected benefits of, common risks of, serious risks of, and alternatives to opioids before starting or continuing opioid therapy and should involve patients meaningfully in decisions about whether to start opioid therapy.", "These actions are not consistent with the 2016 CDC Opioid Prescribing Guideline and have contributed to patient harm, including untreated and undertreated pain, serious withdrawal symptoms, worsening pain outcomes, psychological distress, overdose, and suicidal ideation and behavior (66\u201371). Since release of the 2016 CDC Opioid Prescribing Guideline, new evidence has emerged on the benefits and risks of prescription opioids for both acute and chronic pain, comparisons with nonopioid pain treatments, dosing strategies, opioid dose-dependent effects, risk mitigation strategies, and opioid tapering and discontinuation (7\u201311).", "Although this update includes content on pain management for patients with opioid use disorder and one recommendation on management of opioid use disorder as a complication of opioid use, recommendations on opioids used specifically as medications for opioid use disorder are not the focus of this clinical practice guideline. More detailed recommendations on management of patients with opioid use disorder are available in the American Society of Addiction Medicine (ASAM) National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (96).", "Evidence exists of increased risk for serious harms (including opioid use disorder and overdose) with long-term opioid therapy that appears to rise with increase in opioid dosage, without a clear threshold below which there is no risk (7). No validated, reliable way exists to predict which patients will experience serious harm from opioid therapy and which patients will benefit from opioid therapy (7). Discontinuing opioids after extended periods of continuous opioid use can be challenging for clinicians and patients. Tapering or discontinuing opioids in patients who have taken them long term can be associated with clinically significant risks (68), particularly if opioids are tapered rapidly or patients do not receive effective support.", "If additional opioids are required (e.g., for superimposed severe acute pain), they should be continued only for the duration of pain severe enough to require additional opioids, returning to the patient\u2019s baseline opioid dosage as soon as possible, including an appropriate taper to baseline dosage if additional opioids were used around the clock for more than a few days (see Recommendation 6). Patient education and discussion before starting outpatient opioid therapy are critical so that patient preferences and values can be understood and used to inform clinical decisions. Clinicians should ensure that patients are aware of expected benefits of, common risks of, serious risks of, and alternatives to opioids before starting or continuing opioid therapy and should involve patients in decisions about whether to start opioid therapy."], "title": "CDC Clinical Practice Guideline for Prescribing Opioids for Pain \u2014 United States, 2022 | MMWR"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129223/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129223/", "description": "In response to the opioid epidemic and new guidelines, many patients on high-dose long term opioid therapy (LTOT) for chronic pain are getting tapered off opioids. As a result, a unique clinical challenge is emerging: while many on LTOT have poor pain ...", "snippets": ["Awareness of the science of the neuroplasticity effects of repeated use of opioids is necessary to better manage these patients with complex challenges. In response to the role of excess prescription opioid use in the opioid epidemic and emerging data regarding excess risks associated with long term opioid therapy (LTOT) for pain, the new CDC Guideline for Prescribing Opioids for Chronic Pain proposed an upper safe limit of 90 milligram (mg) morphine equivalent daily (MMED), and a recommendation for opioid tapering and eventual cessation among those above safe limits if the risk benefit balance is not favorable.1 An estimated 20% of patients on LTOT for non-cancer pain in primary care report severe pain-related problems, high psychiatric illness load and addictive behaviors including aberrancies that significantly limited their life, often with high opioid doses,2 i.e.", "Patient was reluctant to pursue OUD care as local clinic was able to provide buprenorphine only if patient was willing to participate in onerous intensive outpatient program (IOP) requiring daily visits and they were explicit that pain will not be and cannot be addressed by buprenorphine (a common misconception in addiction world). Because of this experience, the patient was resistant to buprenorphine and methadone, and methadone was too risky considering his medical state. The pain clinic did not have buprenorphine availability at that time. Based on a harm reduction approach, patient was started back on oxycodone under close supervision (Weekly physician visits for prescription, urine toxicology and counselling, and close family supervision) with intention of keeping the patient engaged in treatment and see if heroin use would stop once pain is controlled (as patient claimed it would).", "In this manuscript, (1) we first provide a commentary supported by available evidence on how the complex neuroplastic and behavioral effects associated with opioid dependence and tolerance could modulate pain and other clinical symptoms among patients on LTOT and undergoing taper, and (2) then describe management principles that offer practical guidance to clinicians based on the above and offer some recommendations regarding opioid taper and management.", "Correspondence should be addressed to Ajay Manhapra MD, VA Hampton Medical center, PRIME 5, 100 Emancipation Drive, Hampton, VA 23667, ude.elay@arpahnam.yaja \u00b7 The publisher's final edited version of this article is available at Subst Abus \u00b7 In response to the opioid epidemic and new guidelines, many patients on high-dose long term opioid therapy (LTOT) for chronic pain are getting tapered off opioids.", "The explanations for this phenomenon lie in a deeper understanding of how opioid tolerance and dependence interact with pain, analgesia, relief and other related psychological symptoms through reward mechanisms and drive patients\u2019 opioid need. In this manuscript, (1) we first provide a commentary supported by available evidence on how the complex neuroplastic and behavioral effects associated with opioid dependence and tolerance could modulate pain and other clinical symptoms among patients on LTOT and undergoing taper, and (2) then describe management principles that offer practical guidance to clinicians based on the above and offer some recommendations regarding opioid taper and management.", "The explanations for this phenomenon lie in a deeper understanding of how opioid tolerance and dependence interact with pain, analgesia, relief and other related psychological symptoms through reward mechanisms and drive patients\u2019 opioid need.", "In response to the opioid epidemic and new guidelines, many patients on high-dose long term opioid therapy (LTOT) for chronic pain are getting tapered off opioids. As a result, a unique clinical challenge is emerging: while many on LTOT have poor pain control, functional decline, psychiatric instability, aberrancies and misuse, these issues may often worsen with opioid tapering.", "A 62-year-old patient with multifocal chronic pain syndrome and brittle diabetes with peripheral neuropathy following complications of liver transplant over a decade back for liver failure from for transfusion acquired hepatitis C, was on oxycodone 10 mg 4 times a day and gabapentin for over a decade. The pain started getting worse a year back and patient used some extra oxycodone and started drinking alcohol to treat pain. PCP tapered patient off opioids because of aberrancy.", "Dependence (not necessarily addiction), when well established, interacts bidirectionally and dynamically with pain, other symptoms, stress, sleep and psychological distress causing significant lability of all these, driving up the perceived need for opioids and other medications, especially psychoactive ones, to control various symptoms.", "Once considered in this light, pain relief amounts to more than a reduction in physical sensation of pain (analgesia) that is often measured clinically using pain scales and mediated by nociceptive neural pathways, but also involves a relief in the affective components of pain experience.7 Newer neurobiological understanding posit that pain relief involves a significant measure of affective \u201crewarding\u201d experience (see box 1 for definition) mediated through mesolimbic reward and learning pathways involving endogenous opioid system, separate from pain pathways. The same relief-reward pathway", "The pain relief from fentanyl patch reapplication was minimal and consistently wearing off after one day and the oxycodone gave minimal relief for about an hour. Patient was spending the other two days in bed or in chair with legs up, unable to do even minimally physically challenging activities.", "While LTOT can lead to poorly controlled pain, poor psychosocial and functional status, psychiatric instability, aberrancies and misuse among a proportion of patients, the logical therapeutic intervention of opioid tapering and discontinuation, on the other hand can cause persistent worsening of these same issues (archetypal patient story in box 1), leading to confusing clinical scenarios and sometimes disastrous consequences including death.5 Such challenging clinical scenarios will likely be more common in the coming years with mounting pressure to adhere to safe upper dose limits.", "As a result, a unique clinical challenge is emerging: while many on LTOT have poor pain control, functional decline, psychiatric instability, aberrancies and misuse, these issues may often worsen with opioid tapering. Currently, a clear explanation and practical guidance on how to manage this perplexing clinical scenario is lacking.", "Opioid tapering, a seemingly logical intervention in this situation, may lead to worsening of pain, function and psychiatric symptoms due to development of protracted abstinence syndrome. We offer practicing clinicians management principles and practical guidance focused on management of CPD in addition to chronic pain in these difficult clinical scenarios.", "An opioid taper can be considered successful only if the probable risk improvement with dose reduction can be balanced with the degree of achievement of goals that are important to patient, namely stability or improvement in pain and function, avoiding instability and harm related to medical, psychiatric and psychological conditions and avoiding significant protracted abstinence syndrome.", "The pain relief from fentanyl patch reapplication was minimal and consistently wearing off after one day and the oxycodone gave minimal relief for about an hour. Patient was spending the other two days in bed or in chair with legs up, unable to do even minimally physically challenging activities. Patient was despondent as a big family event was coming up in 3 weeks and the patient would not be able to perform duties as the head of the family because of the physical limitations. The patient was diagnosed with complex persistent opioid dependence and was initiated on buprenorphine/naloxone 8/2 milligram sublingually twice a day.", "In response to the role of excess prescription opioid use in the opioid epidemic and emerging data regarding excess risks associated with long term opioid therapy (LTOT) for pain, the new CDC Guideline for Prescribing Opioids for Chronic Pain proposed an upper safe limit of 90 milligram (mg) morphine equivalent daily (MMED), and a recommendation for opioid tapering and eventual cessation among those above safe limits if the risk benefit balance is not favorable.1 An estimated 20% of patients on LTOT for non-cancer pain in primary care report severe pain-related problems, high psychiatric illne"], "title": "The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentary - PMC"}, "https://www.nps.org.au/professionals/opioid-tapering-algorithm-text-version": {"url": "https://www.nps.org.au/professionals/opioid-tapering-algorithm-text-version", "description": "Consider specialist input if the patient is experiencing serious challenges, or if the main problem is opioid dependency rather than pain.  \u00b7 When a patient is taking opioids, there are several clinical situations where tapering could be considered.", "snippets": ["Consider specialist input if the patient is experiencing serious challenges in tapering. The algorithm ends here for these patients.  \u00b7 Revisit the patient\u2019s beliefs and concerns about tapering opioids.", "These may include increased pain, withdrawal symptoms, or previously unrecognized opioid use disorder. If challenges are encountered, pause the taper and re-evaluate the patient\u2019s goals, pain, clinical status, coping mechanisms, and tapering rate.", "This is an accessible text version of the NPS MedicineWise opioid tapering algorithm, 2020", "Patients who are tapering opioids may encounter challenges during the taper."], "title": "Opioid tapering algorithm, a flowchart - NPS MedicineWise"}, "https://www.nps.org.au/news/5-steps-to-tapering-opioids": {"url": "https://www.nps.org.au/news/5-steps-to-tapering-opioids", "description": "Tapering opioids may not worsen pain, and recent evidence suggests that it improves function and quality of life. Find out more about how to prepare a successful tapering plan for patients using opioids.", "snippets": ["In situations where longer term opioid treatment has been maintained (often for many years) without meaningful improvement in pain and function, the recommended approach is slow tapering and stopping completely if possible.  \u00b7 One practical strategy is to reduce the daily opioid dose each month by 10%\u201325% of the dose you are starting the taper from.", "Another systematic review10 suggests that tapering opioids can improve pain, functioning and quality of life. In this review, several studies evaluated strategies for effective reduction of long-term (> 3 months) opioids.10,11 These were:", "Multidisciplinary pain management addresses the different aspects of chronic pain including the biopsychosocial impact on the individual.18 The efficacy of a coordinated approach has been recognised to reduce pain severity, and improve mood.18 \u00b7 Of course, there will be cases where multidisciplinary support is not available, leaving GPs to work alone with their patients to implement tapering plans.", "Multidisciplinary pain management addresses the different aspects of chronic pain including the biopsychosocial impact on the individual.18 The efficacy of a coordinated approach has been recognised to reduce pain severity, and improve mood.18 \u00b7 Of course, there will be cases where multidisciplinary support is not available, leaving GPs to work alone with their patients to implement tapering plans. To increase chances of success, undertake opioid tapering with motivated patients11 and slowly reduce opioid doses with their input.8,11", "Withdrawal symptoms and their severity vary among patients. For patients on long-term opioid therapy who have developed opioid dependence, extended withdrawal symptoms can last for weeks or months.24  \u00b7 Consider seeking multidisciplinary advice or support for patients who are having difficulty with tapering.", "an emphasis on non-pharmacological and self-management strategies such as cognitive behavioural therapy (CBT) or mindfulness meditation \u00b7 multidisciplinary care through interdisciplinary pain programs ... While current Australian guidelines recommend regular follow-up visits during opioid tapering,12 it is important to acknowledge that weekly visits may not be feasible for patients or practices.", "To increase chances of success, undertake opioid tapering with motivated patients11 and slowly reduce opioid doses with their input.8,11 \u00b7 Consider leveraging networks when planning to taper opioids eg, coordinating medication management reviews with a local pharmacist. Encourage patients to try online pain management programs and to explore local community pain support groups.", "Download the NPS MedicineWise resource: Starting a conversation about opioid tapering with your patients  \u00b7 Effective pain management planning allows the patient to set specific meaningful and realistic goals that emphasise active self-management.1,16 Self-management strategies can include:1,17 \u00b7 cognitive behavioural therapy (CBT) techniques such as setting realistic goals, pacing activities and challenging unhelpful thoughts", "Another systematic review10 suggests that tapering opioids can improve pain, functioning and quality of life. In this review, several studies evaluated strategies for effective reduction of long-term (> 3 months) opioids.10,11 These were: ... an emphasis on non-pharmacological and self-management strategies such as cognitive behavioural therapy (CBT) or mindfulness meditation \u00b7 multidisciplinary care through interdisciplinary pain programs", "It helps to have set clear expectations from the beginning of treatment about the expected length of treatment, the opioid dosing thresholds, how effectiveness is to be measured and what an exit strategy (discontinuing opioids) will entail.14 \u00b7 If the patient knows that tapering is part of opioid treatment, they will be more likely to be willing participants in opioid tapering.", "Tapering opioids may not worsen pain, and recent evidence suggests that it improves function and quality of life. Find out more about how to prepare a successful tapering plan for patients using opioids."], "title": "5 steps to tapering opioids for patients with chronic non-cancer pain - NPS MedicineWise"}, "https://www.ncbi.nlm.nih.gov/books/NBK458655/": {"url": "https://www.ncbi.nlm.nih.gov/books/NBK458655/", "description": "This chapter addresses the scope of the problem of pain in the United States and its association with opioids, and the effectiveness of pharmacologic (both opioid and nonopioid) and nonpharmacologic treatments that may, alone or in combination, help individuals manage pain.", "snippets": ["The first section summarizes the scope of the problem of pain, focusing in particular on chronic, or persistent, pain, the form most associated with problematic use of opioids. The chapter then presents a detailed discussion of the various pain treatment modalities, reviewing in turn opioid analgesics, nonopioid pharmacologic treatments, interventional pain therapies, and nonpharmacologic treatments.", "Therefore, combining multiple therapeutic modalities, nonpharmacologic and pharmacologic (nonopioid and opioid), holds promise not only to temper the ongoing pain but also to help return the nervous system and its owner back to a less painful and more functional state. It is significant, then, that many of the nonpharmacologic techniques are reimbursed poorly if at all by third-party payers, creating a disincentive to provide this effective care for patients.", "Similarly, the use of gabapentin or pregabalin in the immediate preoperative setting has the potential to decrease the need for postsurgical opioids (Tan et al., 2015a). Research is ongoing to identify strategies that can decrease the risk of acute pain developing into persistent pain (McGreevy et al., 2011). It is important to emphasize that the term \u201cpain management\u201d has not been clearly defined and sometimes is used erroneously to denote solely pharmacologic tools. Yet pain management may involve the use of a number of tools\u2014both pharmacologic and nonpharmacologic\u2014to relieve pain and improve function and quality of life.", "The guideline further recommends consideration of opioid tapering when there is no evidence of improvement in pain or function, particularly when the opioid dose has reached more than 50 morphine milligram equivalents (MME) with or without added benzodiazepines or signs of harm (Dowell et al., 2016)."], "title": "Pain Management and the Intersection of Pain and Opioid Use Disorder - Pain Management and the Opioid Epidemic - NCBI Bookshelf"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018705/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018705/", "description": "Oxycodone is widely used to alleviate moderate-to severe acute pain, It is an effective analgesic for many types of pain, and is especially useful for paroxysmal spontaneous pain, steady pain, allodynia associated with postherpetic neuralgia, and it is ...", "snippets": ["In 2011, following chemical and physical manipulation, an extended-release form of oxycodone was developed in order to maintain its rate-controlling mechanism. This new formulation significantly improved analgesia among patients with moderate-to-severe chronic osteoarthritis pain with an adverse event profile similar to that of other opioids.", "Oxycodone is an analgesic opioid medication that is generally used for the relief of moderate-to-severe pain. It was first developed by German researchers in 1916 from opium-derived thebaine (1). Oxycontin was approved by the FDA in 1995, and was introduced into the United States market in 1996 (2).", "Oxycodone is widely used to alleviate moderate-to severe acute pain, It is an effective analgesic for many types of pain, and is especially useful for paroxysmal spontaneous pain, steady pain, allodynia associated with postherpetic neuralgia, and it is also increasingly used in the management of cancer-related and chronic pain, oxycodone has been found to improve the quality of life of patients with many types of pain.", "Oxycodone is metabolized by the cytochrome p450 enzyme system in the liver. Only 10% is excreted unchanged in urine (4, 5). Because it is metabolized by CYP3A4 and CYP2D6 enzymes, oxycodone is prone to pharmacokinetic drug interactions (6)."], "title": "Use of Oxycodone in Pain Management - PMC"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC315480/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC315480/", "description": "Ben enjoyed 22 years in recovery ... the time of his accident, the emergency room physician successfully managed his initial pain with a combination of bed rest, cyclobenzaprine, and oxycodone....", "snippets": ["Ben called back 2 days later to report a marked increase in pain, so his physician changed his medication to hydrocodone. When Ben called again in another 2 days, he asked to be given oxycodone, saying that the hydrocodone was not providing the pain relief he needed.", "Drug names: amitriptyline (Elavil, Endep, and others), butorphanol (Stadol and others), cyclobenzaprine (Flexeril and others), gabapentin (Neurontin), hydrocodone (Lortab and others), hydromorphone (Dilaudid and others), meperidine (Demerol and others), nalbuphine (Nubain and others), oxycodone (Percocet and others), pentazocine (Talwin and others), propoxyphene (Darvon and others), tramadol (Ultram).", "Ben enjoyed 22 years in recovery from addiction to alcohol, was gainfully employed, and had an active and stable family life with his wife and 2 children before suffering a back injury in an auto accident 3 years ago that resulted in a moderately severe pain syndrome. At the time of his accident, the emergency room physician successfully managed his initial pain with a combination of bed rest, cyclobenzaprine, and oxycodone.", "The choice of pain medication is based on the World Health Organization's stepladder approach for mild, moderate, and severe pain.9 Step 1, mild pain, can be treated with acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors. Step 2, moderate pain, can be treated with the same agents with the addition of a weak opioid such as codeine or hydrocodone. Step 3, severe pain, should be treated with strong opioids such as morphine, oxycodone, hydromorphone, or methadone."], "title": "Successful Pain Management for the Recovering Addicted Patient - PMC"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808679/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808679/", "description": "Study findings reveal continued opioid reduction and enduring pain stability for a substantial fraction of patients, 2 to 3 years after a patient-centered voluntary opioid tapering program.We previously reported promising results for a 4-month patient-centered ...", "snippets": ["Since baseline, 11 (52%) of the current sample reported pain reduction, and 12 (57%) reported reduced pain from the 4-month follow-up to the 2- to 3-year follow-up.", "Better data are needed to understand how tapering methodology\u2014including voluntary vs involuntary patient participation\u2014impacts safety and outcomes. We previously reported results for a 4-month voluntary patient-centered opioid tapering study in 51 patients from Colorado.3 Patients with noncancer chronic pain taking long-term opioids at community suburban and rural pain clinics were provided education about the benefits of opioid reduction (reduced health risks without increased pain) by their prescribing physician.", "The current study aimed to report long-term outcomes on pain intensity and daily opioid use for the subset of voluntarily tapered patients we were able to contact. Using email and telephone outreach up to 3 years later, we made contact with 44% of our original sample (M = 156 weeks, SD = 36.72; range = 98\u2013203 weeks) and 1 additional patient who was not reached at the initial follow-up. Brief telephone interviews were used to collect average pain intensity and current opioid use.", "Key questions remain about the durability of effects and possible risks after opioid reduction. We provide the longest follow-up data to date for prospective opioid tapering: 2- to 3-year follow-up for pain intensity and daily opioid use in a subset of patients from our original 4-month opioid tapering study.", "We provide the longest follow-up data to date for prospective opioid tapering: 2- to 3-year follow-up for pain intensity and daily opioid use in a subset of patients from our original 4-month opioid tapering study.", "Research on prescription opioid tapering is scant, low in quality, and minimal data exist for tapering outcomes exceeding 1 year.2,8,12 Most data exist for intensive, inpatient and outpatient programs, with follow-up timepoints that do not exceed 1 year.2,12 For example, a study by Huffman et al.8 reported retrospective analysis of data for patients with chronic pain after an intensive outpatient interdisciplinary pain management program, showing improvements in opioid cessation, but return-to-use rates were 10.5% at 6 months and 30.7% at 1 year.", "Among reachable patients, the effect of time on change in MEDD from baseline to 4 months to 2 to 3 years was significant. Since baseline, 20 (95%) of the current sample reduced MEDD, and 15 (71%) further reduced MEDD at 2- to 3-year follow-up. There was no effect of time on change in pain intensity from baseline to 4 months to 2 to 3 years.", "Twenty-three patients (44% of original sample) responded to contact attempts through telephone and reported their average pain intensity and current opioid use. Opioid doses were converted to morphine equivalent daily dose (MEDD).", "Recent work also indicates increased risks of opioid overdose and suicide for veterans after opioid tapering.10 More recently, a study by Nicholas et al.9 showed that after cognitive-behavioral therapy-based interdisciplinary treatment for chronic pain, the use of opioids was significantly reduced, and these gains were maintained over the 12-month follow-up."], "title": "Patient-centered prescription opioid tapering in community outpatients with chronic pain: 2- to 3-year follow-up in a subset of patients - PMC"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843113/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843113/", "description": "Pharmacists are well positioned to approach patients and work within a multidisciplinary team to initiate and monitor an opioid taper and to increase the success of opioid reduction while minimizing adverse events and harm.", "snippets": ["For patients with CNCP using opioids and experiencing serious challenges in tapering, the Guideline recommends a formal multidisciplinary program.2 This may also apply for those on extremely high doses of opioids where alternative methods such as switching to buprenorphine/naloxone for tapering may be preferred.", "Remarks in the Guideline recognize the cost of formal multidisciplinary opioid reduction programs and their limited availability/capacity. Alternatives proposed include a variety of health professionals who can collaborate in the care of the patient (e.g., primary care physician, nurse, pharmacist, physical therapist, others). A naloxone kit is recommended for anyone on opioid therapy. The Guideline suggests considering naloxone especially while switching opioids.2 As patients taper and discontinue opioids, they are at risk of inadvertent or unintentional overdose due to loss of tolerance.", "Expert opinion on strategies for opioid tapering is provided in the Guideline2 and outlined in Box 1. Consideration of a multidisciplinary and/or team-based approach is associated with success in opioid tapering.6 Linked to the Guidelines is an information sheet for patients, available through the National Pain Centre.7", "The Guideline directs prescribers to collaborate with pharmacists to support opioid tapering. A multidisciplinary or team-based approach is associated with success in tapering."], "title": "Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions - PMC"}, "https://nam.edu/best-practices-research-gaps-and-future-priorities-to-support-tapering-patients-on-long-term-opioid-therapy-for-chronic-non-cancer-pain-in-outpatient-settings/": {"url": "https://nam.edu/best-practices-research-gaps-and-future-priorities-to-support-tapering-patients-on-long-term-opioid-therapy-for-chronic-non-cancer-pain-in-outpatient-settings/", "description": "Introduction Ensuring high-quality, respectful, and appropriate management of chronic non-cancer pain (CNCP) in the context of the US opioid crisis is a critical and complex endeavor. At the [\u2026]", "snippets": ["Tamboli, M., E. R. Mariano, K. E. Gustafson, B. L. Briones, O. O. Hunter, R. R. Wang, T. K. Harrison, A. Kou, S. C. Mudumbai, T. E. Kim, P. F. Indelli, and N. J. Giori. 2019. A multidisciplinary patient-specific opioid prescribing and tapering protocol is associated with a decrease in total opioid dose prescribed for six weeks after total hip arthroplasty.", "Similarly, the goal of the taper may need to change from one of complete elimination of the opioid therapy to one involving a reduction to the lowest effective dose as guided by assessment of patient function, activity goals, and pain levels. Greater use of interdisciplinary teams and psychological support for these patients during the taper should improve the likelihood of a successful taper, although the evidence for use of interdisciplinary teams in the process has not been sufficiently validated by studies.", "Multidisciplinary in-hospital teams improve patient outcomes: A review. Surgical Neurology International 5(7 Suppl):S295\u2013S303. https://doi.org/10.4103/2152-7806.139612. Henry, S. G., D. A. Paterniti, B. Feng, A. M. Iosif, R. L. Kravitz, G. Weinberg, P. Cowan, and S. Verba. 2019. Patients\u2019 experience with opioid tapering: A conceptual model with recommendations for clinicians.", "In addition, efforts such as the coprescription of naloxone can help decrease the risks of a taper . More research is needed on the use of adjunctive medications, managing withdrawal effectively, approaches for coexisting behavioral health disorders, and strategies for safely tapering polypharmacy patients to ensure that protocols being followed are evidence-based and do not cause patients additional physical or psychological harm.", "In some cases, these \u201clegacy\u201d patients are at increased risk for morbidity if they are taking other high-risk medications in combination with opioids . Unfortunately, data regarding the best way to proceed with care for these patients in terms of opioid maintenance or tapering are lacking . This paper focuses on key decision points and available evidence to support tapering strategies for specific patient populations of long-term opioid use being treated for CNCP in the outpatient setting.", "Beyond prescribing the lowest and shortest opioid course that is effective for managing acute pain, protocols for tapering post-surgery, including the use of multidisciplinary and patient-specific tapering protocols as soon as possible is important, and certainly before opioid tolerance has built up . After opioid tolerance has been established, a taper becomes much harder.", "Addressing behavioral health needs is important in the treatment of patients on chronic opioids and those who require tapering. Patient care should involve collaboration between the mental health provider and the provider who is managing the opioid taper. To facilitate the diagnosis of behavioral health issues in CNCP patients, providers can use several patient- and/or staff \u2013 administered assessment tools to screen for behavioral health or SUDs.", "Providers should inform patients that their tolerance can decrease quickly in response to a taper and emphasize the risk of an overdose . In terms of non-pharmacologic pain management interventions, cognitive behavioral therapy (CBT) is effective in durably decreasing chronic pain intensity and improving function, particularly in select groups of patients . While evidence exists specifically for the use of psychological and mindfulness therapies, multidisciplinary rehabilitation, exercise, and acupuncture for chronic pain, testing has been limited to select indications and popula"], "title": "Best Practices, Research Gaps, and Future Priorities to Support Tapering Patients on Long-Term Opioid Therapy for Chronic Non-Cancer Pain in Outpatient Settings - National Academy of Medicine"}, "https://www.mayoclinic.org/medical-professionals/trauma/news/the-role-of-healthcare-professionals-in-opioid-addiction-prevention/mac-20561321": {"url": "https://www.mayoclinic.org/medical-professionals/trauma/news/the-role-of-healthcare-professionals-in-opioid-addiction-prevention/mac-20561321", "description": "Amid opioid addiction's place as a leading U.S. public health concern, a Mayo Clinic hospitalist and addiction medicine specialist calls for opioid stewardship for healthcare professionals and describes what this entails.", "snippets": [], "title": "The role of healthcare professionals in opioid addiction prevention - Mayo Clinic"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156434/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156434/", "description": "Numerous guidelines targeting the safe use of opioids for chronic pain have been published but substantial challenges persist in the clinical application of best practice recommendations. The purpose of this article is to describe a pragmatic approach ...", "snippets": ["Widely accepted indications for tapering long-term opioid therapy have not been fully established, aside from a patient\u2019s request to discontinue therapy. However, the indications for tapering can be loosely grouped into three categories.21, 22 The first category is comprised of clinical factors indicating that the goals of treatment were not met. For example, inadequate pain reduction in the context of diminishing analgesia, lack of functional improvement, and progression of pain interference in physical, emotional and social functioning.", "Prior to initiating opioid therapy, a complete history and physical examination should be performed. One of the key aspects of the initial examination is to establish the primary pain diagnosis that will be the indication for opioid therapy which will facilitate a targeted assessment of pain intensity.", "The final section outlines several approaches to discontinuing opioid therapy including the potential risks and benefits of this aspect of patient care. This review is not intended to supplant previously published guidelines, specifically, the CDC guidelines. Rather, this review is intended to build on current knowledge to drive the clinical implementation of previously established best practice recommendations for the care of adults receiving long-term opioid therapy. A constellation of spinal cord and brain regions are activated by pain stimuli.", "The purpose of this article is to describe a pragmatic approach to the clinical care of adults with chronic pain receiving long-term opioid therapy. Three key components of care will emphasized including (1) the medical and mental health assessment prior to initiating opioid therapy; (2) clinical surveillance during the course of long-term opioid therapy; and (3) clinical considerations and strategies governing opioid tapering."], "title": "Opioid Management: Initiating, Monitoring and Tapering - PMC"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384622/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384622/", "description": "Collectively, the core research team, information scientist, and local reference panel have expertise in knowledge synthesis, pain management, opioid prescribing and tapering, clinical practice guideline development, interprofessional/collaborative/multidisciplinary practice, knowledge translation, ...", "snippets": ["Nationally applicable guidelines have been developed in the United States and Canada . While both draw from similar bodies of evidence and have a focus on dose limits for new prescribing, the Canadian guidelines made explicit recommendations for tapering, or dose reduction and used the GRADE approach to categorize recommendations as strong (\u201cthe recommendation can be adopted as policy in most situations\u201d) or weak (\u201cpolicymaking will require substantial debate and involvement of various stakeholders\u201d). These guidelines provided a weak recommendation that prescribers consider tapering opioids for people who are on greater than 90 ME per day. These same guidelines however, included a strong recommendation that \u201cpatients using opioids and experiencing serious challenges in tapering\u201d should be referred to formal multidisciplinary care (MDC).", "Collectively, the core research team, information scientist, and local reference panel have expertise in knowledge synthesis, pain management, opioid prescribing and tapering, clinical practice guideline development, interprofessional/collaborative/multidisciplinary practice, knowledge translation, and policy advocacy.", "The entire review process, including research question, search strategy, screening, data extraction, and synthesis was subject to iterative review by the core research team and the local reference panel. We consulted 10 experts from the US and Canada, including investigators from recent systematic reviews and research in this area; clinicians who developed and deliver multidisciplinary care programs; health professionals working in multidisciplinary care settings as well as in primary care including physicians, psychologists and pharmacists; and, a patient with lived experience with opioid tapering and multidisciplinary care.", "Concerns about the contribution of prescribed opioids, and particularly high-dose opioids, continue to mount as do initiatives to reduce prescribing. Evidence around opioid tapering, which can be challenging and potentially hazardous, is not well developed. A recent national guideline has recognized this and recommended referral to multidisciplinary care for challenging cases of opioid tapering."], "title": "Multidisciplinary care for opioid dose reduction in patients with chronic non-cancer pain: A systematic realist review - PMC"}, "https://www.therecoveryvillage.com/oxycodone-addiction/oxycodone-taper/": {"url": "https://www.therecoveryvillage.com/oxycodone-addiction/oxycodone-taper/", "description": "Learn how to taper off oxycodone, including different tapering methods, side effects of withdrawal and detox medications commonly used.", "snippets": ["It should not be used in place of the advice of your physician or other qualified healthcare providers. ... Tapering off Oxycodone How to Taper off Oxycodone Types of Oxycodone Opioids Tapering Methods Common Oxycodone Withdrawal Symptoms Side Effects of Oxycodone Tapering Oxycodone Withdrawal Timeline Medications Used When Tapering off Opioids Can Tapering Your Oxycodone Intake Reduce Withdrawal Symptoms?", "Reducing the dose by 10% per week if the person has been taking oxycodone for less than a year \u00b7 Whenever withdrawal symptoms present themselves, this usually indicates that the taper is too quick. Fortunately, this can be managed by pausing or slowing the rate of the taper. Tapering off oxycodone can take months.", "For this reason, titration tapering should not be attempted with oxycodone, which does not completely dissolve in water. Stopping oxycodone cold turkey is not recommended due to the risk of severe withdrawal symptoms, which can lead to relapse and complications like dehydration. Tapering is a safer method of stopping oxycodone and can help support your goal of quitting oxycodone, slowly easing you off the drug.", "Jessica Pyhtila is a Clinical Pharmacy Specialist based in Baltimore, Maryland with practice sites in inpatient palliative care and outpatient primary care at the Department of Veteran Affairs. Read more ... Oxycodone Addiction: Symptoms, Complications and Treatment Tramadol vs. Oxycodone How To Taper off Codeine How Long Does Oxycodone Stay In Your System?"], "title": "How to Taper off Oxycodone: Methods, Side Effects & Timeline"}, "https://stanfordhealthcare.org/medical-conditions/pain/pain/treatments/non-pharmacological-pain-management.html": {"url": "https://stanfordhealthcare.org/medical-conditions/pain/pain/treatments/non-pharmacological-pain-management.html", "description": "Learn more about non-pharmacological pain management, with strategies like neurostimulation, hypnosis, comfort therapy, and physical therapy.", "snippets": ["Examples of these non-pharmacological pain management techniques include the following:", "Manage Your Care From Anywhere. Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill. ... Non-pharmacological pain management is the management of pain without medications.", "Other non-pharmacological pain management may utilize alternative therapies such as comfort therapy, physical and occupational therapy, psychosocial therapy/counseling, and neurostimulation to better manage and reduce pain.", "This method utilizes ways to alter thoughts and focus concentration to better manage and reduce pain. Methods of non-pharmacological pain include:"], "title": "Management of Pain without Medications | Stanford Health Care"}, "https://medlineplus.gov/nondrugpainmanagement.html": {"url": "https://medlineplus.gov/nondrugpainmanagement.html", "description": "There are risks to taking pain medicines, especially opioids. Learn about different techniques and treatments which may help you manage your pain without taking medicines.", "snippets": ["Because of the side effects and risks of pain relievers, you may want to try non-drug treatments first. And if you do need to take medicines, also doing some non-drug treatments may allow you to take a lower dose.", "Article: Cognitive Behavioral Therapy for Insomnia in Pain Management for Nonspecific Chronic...", "Acupuncture is based on the belief that qi (vital energy) flows through the body along paths, called meridians. Practitioners believe that stimulating the acupuncture points can rebalance the qi. Research suggests that acupuncture can help manage certain pain conditions.", "Article: Protocol for a randomised trial of a self-directed digital pain management..."], "title": "Non-Drug Pain Management: MedlinePlus"}, "https://www.ncbi.nlm.nih.gov/books/NBK572296/": {"url": "https://www.ncbi.nlm.nih.gov/books/NBK572296/", "description": "This guideline applies to adult patients with urinary tract infection. The objective is to create an evidence-based and cost-effective strategy for management of UTI in adults.", "snippets": ["For patients with cognitive and/or verbal disability, when analgesic plan involves a caregiver, caregivers should receive additional education on pain assessment. Providers should also carefully assess function and goals with both patient and caregiver. Assess fall risk, cognition, respiratory status, and risk for sleep disordered breathing prior to prescribing opioids. Reduce the initial dose of opioids by 25-50% and titrate slowly to avoid over sedation. Consider using a non-verbal pain scale such as CPOT (Critical Care Pain Observation Tool) or FLACC (Face, Legs, Activity, Cry, and Consolability) to assess efficacy of pain medications.", "Classes of non-opioid medications used for chronic pain and their potential benefits and harms are summarized in Table 7. A successful regimen may combine low doses of different types of pain medications to treat different mechanisms of perceived pain simultaneously, increasing medication effectiveness while limiting the risk of toxicity.", "CBD is not recommended for first-line therapy for the treatment of chronic pain. However, patients who have failed other treatments or are opioid dependent may be started on low (5\u201310 mg twice daily) doses, with slow increases of dose.81 Of note, these products are not regulated and therefore it is unclear how to determine dose or quality so these products should be considered with caution. Consider prescribing systemic or topical non-opioid medications as an adjunct to the non-pharmacologic treatments noted above.", "Use past experience to guide the decision to start membrane stabilizers (anticonvulsants) and other non-opioid therapies and to determine initial doses. As with all medical decisions, carefully consider risks and benefits. Short-term opioid therapy may be appropriate for acute pain management to allow for rehabilitation."], "title": "Pain Management - NCBI Bookshelf"}, "https://www.cdc.gov/overdose-prevention/manage-treat-pain/nonopioid-therapies.html": {"url": "https://www.cdc.gov/overdose-prevention/manage-treat-pain/nonopioid-therapies.html", "description": "Learn about nonopioid options to manage pain that may work better with fewer risks and side effects.", "snippets": ["Other options, including therapies that don't involve medications, may work just as well or better and have fewer risks and side effects. You can talk to your doctor about ways to manage your pain that do not involve prescription opioids. Patients with pain should receive treatment that provides the greatest benefit relative to risks. Evidence suggests that some nonopioid treatments used for many types of pain, including therapies that don't involve medications, may actually work better for some conditions and have fewer risks and side effects.", "About Prevention Managing Substance Use Disorders Health Equity Data Resources Additional HHS Resources Overdose Prevention Resources Management and Treatment of Pain All", "Cognitive behavioral therapy (CBT) \u2013 a psychological, goal-directed approach in which patients learn how to modify physical, behavioral, and emotional triggers of pain and stress ... Opioids are just one option for treating pain. Other options work just as well or better and have fewer risks and side effects. Working Together With Your Doctor to Manage Your Pain"], "title": "Nonopioid Therapies | Overdose Prevention | CDC"}, "https://www.cdc.gov/overdose-prevention/hcp/clinical-care/nonopioid-therapies-for-pain-management.html": {"url": "https://www.cdc.gov/overdose-prevention/hcp/clinical-care/nonopioid-therapies-for-pain-management.html", "description": "Nonopioid therapies as an alternative to opioids for pain management.", "snippets": ["For additional information and examples regarding nonopioid and noninvasive nonpharmacologic therapy approaches for treating acute pain, please refer to Recommendation 1 in the 2022 Clinical Practice Guideline ... Refer to Recommendation 1 in the 2022 Clinical Practice Guideline for additional information and examples of nonopioid therapies to treat acute pain.", "Exercise, mind-body interventions, and behavioral treatments (including cognitive behavioral therapy and mindfulness practices) can encourage active patient participation in the care plan and help address the effects of pain in the patient's life. Physical activity can provide additional health benefits such as preventing or reducing symptoms of depression.1 ... Several nonopioid pharmacologic therapies can be used for subacute and chronic pain conditions.", "Clinicians should maximize use of nonpharmacologic and nonopioid therapies as appropriate for the specific condition and patient and only consider opioid therapy for acute pain if benefits are anticipated to outweigh risks to the patient. Many acute pain conditions can often be managed most effectively with nonopioid medications. Noninvasive and nonpharmacologic approaches to acute pain also have the potential to improve pain and function without risk for serious harms.", "Clinicians should maximize use of nonpharmacologic and nonopioid pharmacologic therapies as appropriate for the specific condition and patient and only consider initiating opioid therapy if expected benefits for pain and function are anticipated to outweigh risks to the patient."], "title": "Nonopioid Therapies for Pain Management | Overdose Prevention | CDC"}, "https://effectivehealthcare.ahrq.gov/products/nonopioid-chronic-pain/protocol": {"url": "https://effectivehealthcare.ahrq.gov/products/nonopioid-chronic-pain/protocol", "description": "I. Background and Objectives for the Systematic Review Understanding Chronic Pain Chronic pain is typically defined as pain lasting at least 3 to 6 months or that which persists past the time for normal tissue healing.1 From a strictly biological perspective, pain is activation of the sensory ...", "snippets": ["I. Background and Objectives for the Systematic Review Understanding Chronic Pain Chronic pain is typically defined as pain lasting at least 3 to 6 months or that which persists past the time for normal tissue healing.1 From a strictly biological perspective, pain is activation of the sensory nervous system's nociceptive and hypothalamic-pituitary-adrenal axis.2 Adding to the complexity of chronic pain are its diverse origins and the subjective experience of a sufferer.", "The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain recommends that nonopioid therapy is preferred for the treatment of chronic pain.11 To support, update, and expand such guidelines, synthesis of the current state of the science is required to guide clinicians and inform health policy.", "In patients with chronic pain, what is the comparative effectiveness of nonopioid pharmacologic agents compared to other nonopioid pharmacologic agents for outcomes related to pain, function, and quality of life, after short-term treatment duration (3 to 6 months), intermediate-term treatment duration (6 to 12 months), and long-term treatment duration (\u226512 months)? How does effectiveness or comparative effectiveness vary depending on: (1) the specific type or cause of pain, (2) patient demographics, (3) patient comorbidities, (4) the dose of medication used, (5) the duration of treatment, and (6) dose titration, including tapering.", "Factors that may affect applicability which we have identified a priori include eligibility criteria and patient factors (e.g., demographic characteristics, duration or severity of pain, underlying pain condition, presence of medical and psychiatric comorbidities, event rates and symptom severity in treatment and control groups), intervention factors (e.g., dose and duration of therapy, intensity and frequency of monitoring, level of adherence support, use of co-interventions), comparisons (e.g., type of comparator, effectiveness and feasibility of active comparators), outcomes (e.g., use of unvalidated or nonstandardized outcomes, measurement of short-term or surrogate outcomes), settings (e.g., primary care vs."], "title": "Nonopioid Pharmacologic Treatments for Chronic Pain | Effective Health Care (EHC) Program"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194670/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194670/", "description": "These findings suggest that opioid tapering was associated with increased rates of overdose, withdrawal, and mental health crisis extending up to 2 years after taper initiation. Over the past 2 decades, millions of Americans have been prescribed opioids to manage chronic pain.", "snippets": ["These findings suggest that opioid tapering was associated with increased rates of overdose, withdrawal, and mental health crisis extending up to 2 years after taper initiation. Over the past 2 decades, millions of Americans have been prescribed opioids to manage chronic pain. Although supported by limited evidence, medical educators encouraged the practice of initiating and escalating opioid dosages to address uncontrolled chronic pain, and drug companies aggressively marketed opioids, leading to increases in opioid prescriptions and the number of patients prescribed long-term opioid therapy (LTOT).1 As opioid overdose deaths subsequently increased, state and regional policies have encouraged opioid deprescribing and dose reduction, or tapering, among patients prescribed LTOT.", "This cohort study assesses the longer-term risks of overdose or mental health crisis associated with opioid dose tapering. Patients prescribed long-term opioid therapy are increasingly undergoing dose tapering.", "The frequency of tapering among patients increased substantially after publication of a Centers for Disease Control and Prevention (CDC) opioid prescribing guideline in 2016.2 \u00b7 According to a US Department of Health and Human Services (HHS) guideline,3 dose tapering in patients prescribed LTOT should be considered when the risks of dose continuation outweigh the benefits in terms of pain relief and functional improvement.", "HHS tapering guidelines3 emphasize close follow-up, monitoring for substance use and mental health deterioration, and psychosocial support for patients undergoing opioid tapering after long-term use. Although our results suggest that all tapering patients may benefit from monitoring and support up to 2 years after taper initiation, patients prescribed higher doses may benefit from more intensive support and monitoring, particularly for depression and suicidality.", "In this cohort study of 19 377 patients, in a posttaper period (beginning at least 12 months and extending up to 24 months after taper initiation) vs the pretaper period, the adjusted incidence rate ratios were 1.57 for overdose-withdrawal and 1.52 for a mental health crisis. Both were significant. These findings suggest that opioid dose tapering was associated increased risks of overdose-withdrawal and mental health crisis that persisted up to 2 years after taper initiation.", "Patients prescribed long-term opioid therapy are increasingly undergoing dose tapering. Recent studies suggest that tapering is associated with short-term risks of substance misuse, overdose, and mental health crisis, although lower opioid dose could reduce risks of adverse events over the longer term.", "It is conceivable that opioid dose reduction in patients prescribed LTOT may reduce patient risks of adverse events with longer-term follow-up. We recently reported that opioid dose tapering was associated with higher rates of overdose and mental health crisis during a 1-year follow-up period in a cohort of patients prescribed stable doses of LTOT.11 In the current study, we used an exposure-crossover design to examine longer-term risks of these adverse events among patients who initiated tapers in the cohort.12,13 In an exposure-crossover study, patients serve as their own controls, and event rates are compared before and after patients transition from the unexposed to the exposed state (from pretaper to posttaper).", "According to a US Department of Health and Human Services (HHS) guideline,3 dose tapering in patients prescribed LTOT should be considered when the risks of dose continuation outweigh the benefits in terms of pain relief and functional improvement. A dose-response association has been observed between long-term opioids and overdose risk,4,5 prompting the CDC to caution clinicians about escalating daily opioid doses greater than 50 morphine milligram equivalents (MME).6 On the other hand, opioid tapering may also confer patient risks, including precipitated withdrawal, worsening pain, use of illicit opioids, depression, anxiety, and suicide.7,8,9,10 Research documenting risks associated with tapering, however, has generally examined periods near the time of initial dose reduction or discontinuation."], "title": "Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering - PMC"}, "https://www.cdc.gov/drugoverdose/training/dosing/accessible/index.html": {"url": "https://www.cdc.gov/drugoverdose/training/dosing/accessible/index.html", "description": "So, when I am in pain, I take ... more oxycodone for the same pain over and over\u2026 \u00b7 [Provider] It is likely that reducing your dosage will ultimately make you feel better. ... The correct answer is yes. This patient is taking 90 MME per day, without optimization of nonopioid methods of managing pain. It is reasonable to maximize nonopioid therapy while offering this patient an opioid taper, carefully ...", "snippets": ["To learn more about OUD, the process for diagnosis, and medication-assisted treatment options, review the 5th module of this series: Assessing and Addressing Opioid Use Disorder. ... Chief complaint/reason for visit: Ongoing hip pain, with poor daily function. ... Previous provider recommended physical therapy, although patient admits to not following through with recommended exercises \u00b7 Currently takes extended-release oxycodone 30 mg 2 times daily ... [Provider] Good afternoon. It is good to see you again. At our last visit, we discussed the possibility of tapering your oxycodone.", "Providers should optimize pain management to support the taper and/or discontinuation. Maximize use of nonpharmacological treatments for pain, as well as appropriate nonopioid pharmacologic options. When starting opioid therapy, providers should prescribe IR opioids instead of ER/LA opioids.", "So, when I am in pain, I take oxycodone, and then need to take more oxycodone for the same pain over and over\u2026 \u00b7 [Provider] It is likely that reducing your dosage will ultimately make you feel better. ... The correct answer is yes. This patient is taking 90 MME per day, without optimization of nonopioid methods of managing pain. It is reasonable to maximize nonopioid therapy while offering this patient an opioid taper, carefully explaining the risks and benefits of opioid therapy.", "Patients tapering or discontinuing opioid therapy benefit from a multidisciplinary approach to pain management and frequent, at least weekly, follow-up appointments. Psychological support, especially cognitive behavioral therapy (CBT), combined with other nonpharmacological and nonopioid therapies have proven to be successful."], "title": "Module 6: Dosing and Titration of Opioids: How Much, How Long, and How and When to Stop?"}, "https://emedicine.medscape.com/article/2138678-overview": {"url": "https://emedicine.medscape.com/article/2138678-overview", "description": "A thorough pain assessment is vital to the initial evaluation of a patient and must be performed to guide treatment decisions. Dosing may be done incrementally and titrated to analgesic effect.", "snippets": ["In 2016, the Centers for Disease Control and Prevention (CDC) issued recommendations for prescribing opioids for chronic pain. The recommendations included the following  : Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain.", "If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate. Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how opioid therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.", "Clinicians should evaluate benefits and harms of continued therapy with patients every 3 mo or more frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.", "Before initiating opioid therapy, clinicians should discuss with patients the realistic benefits and known risks of opioid therapy. Clinicians should maximize use of nondrug and nonopioid drug therapies, as these are at least as effective as opioids for many common types of acute pain and are preferred for subacute and chronic pain."], "title": "Opioid Equivalents and Conversions: Overview"}, "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793293": {"url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793293", "description": "This cohort study assesses the longer-term risks of overdose or mental health crisis associated with opioid dose tapering.", "snippets": [], "title": "Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering | Pharmacy and Clinical Pharmacology | JAMA Network Open | JAMA Network"}, "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335575/": {"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335575/", "description": "Among the patients who underwent ... (vs 41.9%). Posttapering patient periods were associated with an adjusted incidence rate of 9.3 overdose events per 100 person-years compared with 5.5 events per 100 person-years in nontapered periods (adjusted incidence rate difference, ...", "snippets": ["These and other widely disseminated recommendations have led to increased opioid tapering among patients prescribed long-term opioid therapy.5,6 However, opioid-related mortality has continued to rise.7 \u00b7 Subsequent US recommendations have advised caution in opioid de-prescribing.8,9 Studies suggest risks of suicidal ideation, transition to illicit opioids, and overdose after opioid tapering and discontinuation.", "In this retrospective cohort study that included 113 618 patients prescribed stable, high-dose opioid therapy, patients in periods following dose tapering, compared with patients before or without tapering, had an adjusted incidence rate ratio of 1.68 for overdose and 2.28 for mental health crisis; both risks were statistically significant.", "Opioid-related mortality and national prescribing guidelines have led to tapering of doses among patients prescribed long-term opioid therapy for chronic pain. There is limited information about risks related to tapering, including overdose and mental health crisis.", "Among the patients who underwent dose tapering, 54.3% were women (vs 53.2% among those who did not undergo dose tapering), the mean age was 57.7 years (vs 58.3 years), and 38.8% were commercially insured (vs 41.9%). Posttapering patient periods were associated with an adjusted incidence rate of 9.3 overdose events per 100 person-years compared with 5.5 events per 100 person-years in nontapered periods (adjusted incidence rate difference, 3.8 per 100 person-years [95% CI, 3.0-4.6]; aIRR, 1.68 [95% CI, 1.53-1.85]). Tapering was associated with an adjusted incidence rate of 7.6 mental health cris"], "title": "Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids - PMC"}}